• Publications
  • Influence
The Third Intergroup Rhabdomyosarcoma Study.
PURPOSE The ultimate goal of the Third Intergroup Rhabdomyosarcoma Study (IRS-III, 1984 to 1991) was to improve treatment outcome in children with rhabdomyosarcoma through clinical trials comparingExpand
  • 825
  • 32
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.
Eighty-nine patients with untreated primary neuroblastomas were studied to determine the relation between the number of copies of the N-myc oncogene and survival without disease progression. GenomicExpand
  • 1,870
  • 26
The intergroup rhabdomyosarcoma study‐I. A final report
The results of treatment of 686, previously untreated patients younger than 21 years with rhabdomyosarcoma or undifferentiated sarcoma, who were entered on Intergroup Rhabdomyosarcoma Study‐I (IRS‐I)Expand
  • 745
  • 11
The intergroup rhabdomyosarcoma study‐II
Background. Intergroup Rhabdomyosarcoma Study (IRS)‐II, (1978–1984) had the general goals of improving the survival and treatment of children with rhabdomyosarcoma (RMS).
  • 637
  • 10
The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial
SummaryFifty-eight patients with high-grade astrocytoma were treated by members of the Childrens Cancer Study Group in a prospective randomized trial designed to study the effectiveness ofExpand
  • 221
  • 10
Inducible plasmid-determined resistance to arsenate, arsenite, and antimony (III) in escherichia coli and Staphylococcus aureus.
Plasmids in both Escherichia coli and Staphylococcus aureus contain an "operon" that confers resistance to arsenate, arsenite, and antimony(III) salts. The systems were always inducible. All threeExpand
  • 174
  • 8
  • PDF
Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2).
Members of the Childrens Cancer Study Group treated 234 eligible patients in a randomized trial designed to study the relative effectiveness of two therapy programs for the treatment of childhood andExpand
  • 299
  • 6
Down syndrome and acute leukemia in children: a 10-year retrospective survey from Childrens Cancer Study Group.
Review of 5406 children with acute lymphoblastic (ALL) or nonlymphoblastic leukemia (ANLL) registered with Childrens Cancer Study Group (CCSG) since 1972 identified 115 patients (2.1%) with DownExpand
  • 186
  • 5
Analysis of prognostic factors in acute lymphoblastic leukemia.
Children with ALL who have a high probability of excellent response, long-term survival, and cure when treated with widely available standard therapy can be identified at the time of diagnosis.Expand
  • 127
  • 5
Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Childrens Cancer Group.
Cytogenetic analyses of pretreatment bone marrows were performed at local institutions as part of Childrens Cancer Group (CCG) protocol CCG-107 for infants less than 1 year of age with previouslyExpand
  • 155
  • 5
  • PDF